ライフサイエンスコーパス: leukotriene B4

1 were not mirrored by other eicosanoids (i.e. leukotriene B4).

2 sion molecule 1, P-selectin, L-selectin, and leukotriene B4.

3 ary membrane protein permeability, IL-8, and leukotriene B4.

4 IL-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4.

5 tion during sepsis and increased circulating leukotriene B4.

6 ed [Ca2+]i, while it inhibited the action of leukotriene B4.

7 the amniotic cavity reveals up-regulation of leukotriene B4.

8 ntly reduced without affecting the levels of leukotriene B4.

9 idase without affecting the bioproduction of leukotriene B4.

10 llular signaling that leads to production of leukotriene B4.

11 in a relative narrow concentration range for leukotriene B4 (100-200 nm).

12 cosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thromboxane B2 , and prostag

13 Rat NADP-dependent leukotriene B4 12-hydroxydehydrogenase (Ltb4dh) catalyze

14 eductase (AO), an enzyme heretofore known as leukotriene B4 12-hydroxydehydrogenase, 15-oxoprostaglan

15 ion of leukotriene B4, (LTB4) and 20-hydroxy-leukotriene B4 (20-OH-LTB4).

16 tors (LM) via metabololipidomics, CO reduced leukotriene B4 (21 +/- 11 versus 59 +/- 24 pg/mouse, 6 h

17 oid metabolites 5-oxo-eicosatetraenoic acid, leukotriene B4 5-hydroxyeicosatetraenoic acid (HETE), 12

18 aT, significantly inhibited the formation of leukotriene B4, a potent chemotactic agent synthesized b

19 CYP4F3A inactivates leukotriene B4, a reaction that has significance for con

20 that BLT2, a G protein-coupled receptor for leukotriene B4 and 12(S)-hydroxyheptadecatrienoic acid (

21 products, MDA, gamma-glutamyl peptides, GGT, leukotriene B4 and 5-HETE.

22 Leukotriene B4 and interleukin-8, known chemoattractants

23 Recently, leukotriene B4 and its high affinity receptor, BLT1, hav

24 sor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small mol

25 ntegrins, in concert with neutrophil-derived leukotriene B4 and other chemoattractants, promote local

26 spect to inflammatory lipid mediators (i.e., leukotriene B4 and PGs) in omental adipose tissue from O

27 ediators including prostaglandin F2alpha and leukotriene B4 and pro-resolving mediators, including re

28 ectious exudates gave higher proinflammatory leukotriene B4 and procoagulating thromboxane B2, as wel

29 e included inflammation initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving me

30 vels of the pro-inflammatory lipid mediators leukotriene B4 and prostaglandin E2 are elevated in the

31 l infiltration and prevented the increase in leukotriene B4 and prostaglandin E2 in response to ische

32 Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated wi

33 n expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant d

34 ase n-6 PUFA-derived lipid mediators such as leukotriene B4 and prostaglandin E2.

35 ities of cell-associated AA mimicked that of leukotriene B4 and PtdCho/PtdIns, while the specific act

36 howing a decrease in BALF levels of IL-8 and leukotriene B4 and the associated reduction of BALF neut

37 onophore (A23187), and the concentrations of leukotrienes B4 and B5, thromboxane A2, prostaglandin E2

38 mbers correlated with the enhanced levels of leukotrienes B4 and C4 and prostaglandin E2 produced aft

39 pha; prostaglandins E1, D2, and F2 alpha and leukotrienes B4 and C4 were detected in lower amounts.

40 secrete the inflammatory eicosanoid products leukotrienes B4 and C4, the cytokines IL-6 and TNF, and

41 on between rs174537 and the ratio of ARA/LA, leukotriene B4, and 5-HETE but no effect on levels of cy

42 ils exposed to chemoattractants (IL-8, FMLP, leukotriene B4, and C5a) failed to show increases in int

43 EIA determined leukotriene B4, and ELISAs quantified TNF, IL-12 and IL-

44 ositol hexakisphosphate, lipopolysaccharide, leukotriene B4, and granulocyte-macrophage colony-stimul

45 h the chemoattractants N-formyl-Met-Leu-Phe, leukotriene B4, and interleukin-8 exhibits threshold beh

46 tion of soluble factors including adenosine, leukotriene B4, and several chemokines.

47 f synthesis of the potent chemotactic factor leukotriene B4, and that process was reversed by rottler

48 ylated peptides, platelet-activating factor, leukotriene B4, and the complement anaphylatoxins.

49 phonuclear leukocyte infiltration induced by leukotriene B4 (approximately 78% inhibition) or phorbol

50 ages and identify Plg-mediated regulation of leukotriene B4 as an underlying mechanism.

51 To determine the opsonin dependence of the leukotriene B4 augmentation of phagocytosis, we assessed

52 While leukotriene B4 augmented both Fc receptor- and complemen

53 Ratios of thromboxane B2,/B3, leukotriene B4/B5, and prostaglandin E2/E1 were reduced

54 -lipoxygenase-deficient mice, the absence of leukotriene B4 biosynthesis did not detectably alter m-B

55 oup V phospholipase A2 (hVPLA2) could elicit leukotriene B4 biosynthesis in human neutrophils through

56 nd of the thiazole series, by inhibiting the leukotriene B4 biosynthesis in the RPAR assay (3 h pretr

57 show that PGE2-G, but not PGE2-EA, inhibits leukotriene B4 biosynthesis, superoxide production, migr

58 RvE1 binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR

59 B4/mg protein, p < .001) generation of ileal leukotriene B4, but did not alter the cyclooxygenase pro

60 N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4, by approximately 65%, but had no effect

61 ctive on the same responses when elicited by leukotriene B4, C5a, FMLP, platelet-activating factor, I

62 The neutrophil count and leukotriene B4 concentration in bronchoalveolar lavage f

63 Importantly, higher leukotriene B4 concentrations (>0.5 mum) and BLT2 agonis

64 Leukotriene B4 decreased in 4-aminopyridine and EPI grou

65 plication of this method to the synthesis of leukotriene B4 demonstrates its utility and extraordinar

66 s, i.e. platelet activating factor (PAF) and leukotriene B4, did not inhibit the responses of peptide

67 In contrast, AACOCF3 potently inhibited leukotriene B4 formation by ionophore-stimulated neutrop

68 s from various mammalian cells and to elicit leukotriene B4 formation from human neutrophils.

69 the release of high mobility group box 1 and leukotriene B4 from the epithelial cells and this releas

70 ociated with significant reductions in ileal leukotriene B4 generation and neutrophilic infiltrate.

71 Two major G-protein-coupled receptors for leukotriene B4 have been identified: the high-affinity r

72 oncentration in exhaled breath condensate of leukotriene B4, hydrogen peroxide and hydrogen ions rose

73 .05), but there was no significant change in leukotriene B4, hydrogen peroxide, or hydrogen ion conce

74 P4F regulators in vitro, effecting increased leukotriene B4 hydroxylation (inactivation).

75 ive prostaglandin E2 (iPGE2), immunoreactive leukotriene B4 (iLTB4), and pain after periodontal surge

76 d in decreased levels of prostaglandin E2 or leukotriene B4 in intestinal polyps or apparently normal

77 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4 in particular could serve as potential bi

78 clusion, we have identified a novel role for leukotriene B4 in the augmentation of neutrophil phagocy

79 In the antiprostacyclin antibody group, leukotriene B4 increased immediately after starting anti

80 Accordingly, leukotriene B4-induced thermal hyperalgesia was mediated

81 study, we explored the effect of the C5 and leukotriene B4 inhibitor Ornithodoros moubata complement

82 dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and c

83 -Leu-Phe (fMLP), platelet-activating factor, leukotriene B4, interleukin-8, or the chemokine RANTES e

84 Leukotriene B4 is a lipid mediator that recently has bee

85 Leukotriene B4 is a proinflammatory lipid mediator whose

86 The levels of leukotriene B4, leukotriene C4/D4, 6-keto-prostaglandin

87 ly increase bronchoalveolar lavage levels of leukotriene B4, leukotriene C4/D4, and thromboxane B2 ab

88 ronchoalveolar lavage fluid was analyzed for leukotriene B4, leukotriene C4/D4, thromboxane B2, prost

89 mplement complex and significantly decreased leukotriene B4 levels in septic pigs.

90 displaced by 5-oxoETE analogues, but not by leukotriene B4, lipoxin A4, or lipoxin B4.

91 e (fMLP)), platelet activating factor (PAF), leukotriene B4 (LTB(4)), C5a anaphylotoxin (C5a), and in

92 -) eosinophils and neutrophils had decreased leukotriene B4 (LTB(4))-dependent chemotactic responses

93 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

94 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

95 lbumin (65.6 versus 53.0 micrograms/ml), and leukotriene B4 (LTB4) (243 versus 0 pg/ml) in BAL fluid

96 Leukotriene B4 (LTB4) activates the G-protein-coupled re

97 Prolonged exposure of PMN to leukotriene B4 (LTB4) afforded dose-dependent inhibition

98 ease in the abundance of the proinflammatory leukotriene B4 (LTB4) and a corresponding decrease in th

99 r the conversion of leukotriene A4 (LTA4) to leukotriene B4 (LTB4) and also possesses an aminopeptida

100 nition systems for other chemotaxins such as leukotriene B4 (LTB4) and fMLP is unknown.

101 mediated by signaling through the chemokine leukotriene B4 (LTB4) and its receptor LTB4R1.

102 Eicosanoids, such as leukotriene B4 (LTB4) and lipoxin A4 (LXA4), may play a

103 on and secretion of interleukin 8 (IL-8) and leukotriene B4 (LTB4) and was prevented by mitochondrial

104 ediators such as prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are implicated in the development

105 mediated) biosynthesis of the lipid mediator leukotriene B4 (LTB4) are pivotal components of host def

106 Important roles for tyrosine kinase Syk and leukotriene B4 (LTB4) are recognized in FcgammaR-mediate

107 i-MCP-1 Abs reduced the peritoneal levels of leukotriene B4 (LTB4) by 59%.

108 x was largely dependent on the generation of leukotriene B4 (LTB4) by neutrophils and their expressio

109 Leukotriene B4 (LTB4) contributes to many inflammatory d

110 The synthetic 13S,14S-epoxide inhibited leukotriene B4 (LTB4) formation by human leukotriene A4

111 ygenase (5LO) and its chemotactic metabolite leukotriene B4 (LTB4) in KSHV biology.

112 23 activates the synthesis and production of leukotriene B4 (LTB4) in myeloid cells, which modulate i

113 ion has demonstrated the mechanistic role of leukotriene B4 (LTB4) in the molecular pathogenesis of l

114 Leukotriene B4 (LTB4) is a chemotactic and cell-activati

115 Leukotriene B4 (LTB4) is a potent activator and chemoatt

116 Leukotriene B4 (LTB4) is a potent chemoattractant for my

117 Leukotriene B4 (LTB4) is a potent chemoattractant for ne

118 Leukotriene B4 (LTB4) is a rapidly synthesized, early le

119 The pro-inflammatory mediator leukotriene B4 (LTB4) is implicated in the pathologies o

120 of airway hyperresponsiveness (AHR) and that leukotriene B4 (LTB4) is involved in the chemotaxis of e

121 Leukotriene B4 (LTB4) is secreted by chemotactic neutrop

122 codynamic (PD) relationship based on ex vivo leukotriene B4 (LTB4) levels in dog.

123 We measured lipoxin A4 (LXA4) and leukotriene B4 (LTB4) levels in EBC collected from patie

124 ith palmitate, enhanced arginase 1 and lower leukotriene B4 (LTB4) levels were detected in macrophage

125 udy was designed to test the hypothesis that leukotriene B4 (LTB4) may have a role in graft rejection

126 We tested the hypothesis that leukotriene B4 (LTB4) mediates the effects of toxin A vi

127 (approximately 80% reduction) in response to leukotriene B4 (LTB4) plus prostaglandin E2 (PGE2) as we

128 5-lipoxygenase (5-LO) activity and increased leukotriene B4 (LTB4) production have been implicated in

129 rease exudate volume, cell infiltration, and leukotriene B4 (LTB4) production in response to zymosan

130 n reported to be a purinoceptor (P2Y7) and a leukotriene B4 (LTB4) receptor (BLTR).

131 99mTc-RP517 is a new leukotriene B4 (LTB4) receptor antagonist developed for

132 ctivity study based around the high-affinity leukotriene B4 (LTB4) receptor antagonist SB 201146 (1)

133 ugh 5'-lipoxygenase or via antagonism of the leukotriene B4 (LTB4) receptor.

134 ted as antagonists of the human cell surface leukotriene B4 (LTB4) receptor.

135 rrow-derived DCs (BM-DCs) express functional leukotriene B4 (LTB4) receptors as observed in dose-depe

136 It has been reported that leukotriene B4 (LTB4) reduces the parasitic load of infe

137 e lymphotoxin-stimulated neovasculature with leukotriene B4 (LTB4) resulted in stable cell adhesion f

138 Mucosal synthesis of the chemoattractant leukotriene B4 (LTB4) significantly increased after I-R

139 Leukotriene B4 (LTB4) stimulates neutrophils to adhere l

140 hat nuclear positioning plays in determining leukotriene B4 (LTB4) synthesis.

141 In human neutrophils, leukotriene B4 (LTB4) triggered rapid decreases in PSDP

142 e demonstrate that the lipid chemoattractant leukotriene B4 (LTB4) was efficacious at causing loss of

143 In 36 preparations, concentration of leukotriene B4 (LTB4) was measured in treated tracheal p

144 Leukotriene B4 (LTB4) was more potent than cysteinyl LTs

145 Leukotriene B4 (LTB4) was originally described as a pote

146 )-mediated C5 activation and also sequesters leukotriene B4 (LTB4) within an internal binding pocket.

147 g by autocoids with opposing actions on PMN: leukotriene B4 (LTB4), a potent chemoattractant, and lip

148 The cellular origin of leukotriene B4 (LTB4), a potent pro-inflammatory molecul

149 They are the main source of leukotriene B4 (LTB4), a potent proinflammatory lipid me

150 Leukotriene B4 (LTB4), a product of the lipoxygenase pat

151 Leukotriene B4 (LTB4), a proinflammatory mediator produc

152 B4(LXB4) blocked PMN migration stimulated by leukotriene B4 (LTB4), a well established agonist for PM

153 glandin E2 (PGE2) and 5-LO-derived products, leukotriene B4 (LTB4), and the biosynthesis interaction

154 s known that 5-lipoxygenase and its product, leukotriene B4 (LTB4), are highly expressed in several h

155 ), and the ratio of SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in th

156 on of leukotrienes, and more specifically on leukotriene B4 (LTB4), for disease induction as well as

157 ), LXA4, and its counterregulatory compound, leukotriene B4 (LTB4), in patients with childhood asthma

158 (TxB2), prostaglandin 6-keto-F1alpha (PGI), leukotriene B4 (LTB4), leukotriene C4D4E4 (LTC4D4E4), in

159 Rat alveolar macrophages produced leukotriene B4 (LTB4), LTC4, and 5-hydoxyeicosatetraenoi

160 than C5a, platelet-activating factor (PAF), leukotriene B4 (LTB4), or FMLP in stimulating Eo chemota

161 onditions and after administration of either leukotriene B4 (LTB4), platelet-activating factor (PAF),

162 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and inte

163 X favors the biosynthesis of proinflammatory leukotriene B4 (LTB4), whereas, in theory, cytoplasmic 5

164 ion of inflammatory mediators, TNF-alpha and leukotriene B4 (LTB4), which are involved in parasite ki

165 eukotoxin (LKT) stimulates the production of leukotriene B4 (LTB4), which is believed to be an import

166 Here, leukotriene B4 (LTB4)-induced PMN influx in ear skin was

167 blocks platelet activating factor (PAF)- and leukotriene B4 (LTB4)-induced responses.

168 l memory, CD8+ T cells through production of leukotriene B4 (LTB4).

169 l-leucyl-phenylalanine (fMLP) is mediated by leukotriene B4 (LTB4).

170 o platelet-activating factor (PAF), C5a, and leukotriene B4 (LTB4).

171 SF), and the eiconsanoids thromboxane A2 and leukotriene B4 (LTB4).

172 tifs, synthetic origins, and bioactions with leukotriene B4 (LTB4).

173 eutrophil production of a second eicosanoid, leukotriene B4 (LTB4).

174 d mediating general neutrophil chemotaxis is leukotriene B4 (LTB4).

175 MLP signal over a competing chemoattractant, leukotriene B4 (LTB4).

176 enrichment of the chemotactic gradient with leukotriene B4 (LTB4).

177 ted a high affinity and specific binding for leukotriene B4 (LTB4, Kd = 0.24 +/- 0.03 nM).

178 s, synthetic N-acetyl-PGP, positive control (leukotriene B4 [LTB4]), or negative control (Hanks' bala

179 ided exogenously) inhibited the formation of leukotriene B4, (LTB4) and 20-hydroxy-leukotriene B4 (20

180 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotri

181 ulated (16.0 +/- 4.9 vs. 80.0 +/- 15.5 pg of leukotriene B4/mg protein, p < .001) generation of ileal

182 th basal (8.0 +/- 1.9 vs. 33.0 +/- 8.1 pg of leukotriene B4/mg protein, p < .05) and ionophore-stimul

183 animals did not produce prostaglandin E2 or leukotriene B4 or C4.

184 dent manner (P < 0.05) but did not attenuate leukotriene B4 or complement-activated serum ECA.

185 Inhibition of leukotriene B4 or integrin rescues maturation and migrat

186 cytes to ATLa but not to the chemoattractant leukotriene B4 or vehicle alone.

187 after stimulation of either neutrophils (by leukotriene B4) or coronary endothelium (by thrombin) in

188 HETE), or lipoxygenase metabolites (5S-HETE, leukotriene B4, or lipoxin A4).

189 Tenascin did not affect leukotriene B4- or fMLP-stimulated expression of beta1 o

190 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is an important in

191 duced 5-[3H]oxoETE binding, whereas 15-HETE, leukotriene B4, platelet-activating factor, IL-8, C5a, a

192 s may involve local intestinal inhibition of leukotriene B4 production and subsequent neutrophilic in

193 of neutrophilic infiltrate, an inhibition of leukotriene B4 production, and a facilitation of mucosal

194 cant decrease in IgE-mediated degranulation, leukotriene B4 production, cytokine secretion, and survi

195 pofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

196 Concentrations of leukotriene B4, prostaglandin E2, and thromboxane B2 rel

197 Plasma levels of histamine, leukotriene B4, prostaglandin E2, prostaglandin F2, pH,

198 The mouse leukotriene B4 receptor (m-BLTR) gene was cloned.

199 B4) activates the G-protein-coupled receptor leukotriene B4 receptor 1 (BLT1) to mediate a diverse ar

200 that signals via its cell surface receptor, leukotriene B4 receptor 1 (BLT1), to attract and activat

201 t 12-S-HHT, but not 16:4(n-3), functions via leukotriene B4 receptor 2 (BLT2).

202 A leukotriene B4 receptor antagonist, ONO 4057, did not si

203 nstrate a unique, non-redundant role for the leukotriene B4 receptor BLT1 in mediating neutrophil rec

204 strategy was applied to a typical GPCR, the leukotriene B4 receptor BLT2, reconstituted in a lipid b

205 erved in human neutrophils pretreated with a leukotriene B4 receptor but not a cysteinyl-leukotriene

206 this study, we investigated the roles of the leukotriene B4 receptor, BLT1, and CXCR3, the receptor f

207 splicing were further investigated with the leukotriene B4 receptor, known for its aberrant responsi

208 e lung tumour burden and genetic deletion of leukotriene B4 receptor-1 (BLT1(-/-)) attenuates this in

209 le nitric oxide synthase, and antagonists of leukotriene B4 receptor.

210 Thus, the data show that the two leukotriene B4 receptors have opposing roles in the sens

211 mmunohistochemical analysis showed that both leukotriene B4 receptors were expressed in peripheral se

212 While leukotriene B4 reconstituted defective phagocytosis in l

213 osatetraenoic acid produced by platelets and leukotriene B4 released from calcium ionophore-activated

214 Leukotriene B4 rescued the suppression of CD36 expressio

215 of this defect, as it leads to activation of leukotriene B4 signaling and induction of the alpha4beta

216 covers a previously undefined role of innate leukotriene B4 signaling as a gatekeeper of the hematopo

217 ve migration toward worms requires paracrine leukotriene B4 signaling between eosinophils.

218 hors show that changing miRNA biogenesis and leukotriene B4 signaling in mice modulates this switch i

219 Inactivation of leukotriene B4 signaling or genetic deficiency of PPARal

220 of collagen I or Matrigel, and chemotaxis of leukotriene B4-stimulated PMN through fibrin gels.

221 cosanoids--e.g., 12(R)-HETE, 12(S)-HETE, and leukotriene B4--stimulated the activation of NF-kappaB r

222 LF levels of total protein, neutrophils, and leukotriene B4 tended to decrease in EPA+GLA patients ov

223 L)-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4 that are responsible, in part, for pulmon

224 ammatory arachidonic acid-derived mediators, leukotriene B4, thromboxane B2, and prostaglandin E2 fro

225 ctions in the generation of pro-inflammatory leukotriene B4, thus LTA4H exhibits opposing pro- and an

226 olites of the 5-lipoxygenase pathway such as leukotriene B4 to activate the peroxisome proliferator-a

227 of phagocytosis, we assessed the ability of leukotriene B4 to modulate neutrophil phagocytosis and t

228 ediated phagocytosis, increased adherence to leukotriene B4-treated neutrophils was limited to comple

229 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4), TRPV4 (5,6-epoxyeicosatrienoic acid [EE

230 spectively) but generated greater amounts of leukotriene B4 upon maximal stimulation (26.6 versus 7.6

231 enylalanine, platelet activating factor, and leukotriene B4 was phosphoinositide-3 kinase-dependent,

232 potent neutrophil activator/chemoattractant leukotriene B4 were measured by mass spectrometry in ski

233 The eicosanoid mediators, thromboxane and leukotriene B4, were also highest in the severe asthma g

234 ntrations of leukotrienes C4, D4, and E4 and leukotriene B4, whereas prostacyclin infusion suppressed

235 elay among neutrophils mediated by the lipid leukotriene B4, which acutely amplifies local cell death